Table 3.
Comparison of clinical factors and dosimetric parameters between patients with grade ≤ 1 pneumonitis and those with grade ≥ 2 pneumonitis
| Parameter | Grade ≤ 1 pneumonitis group (n = 22) | Grade ≥ 2 pneumonitis group (n = 7) | p-value |
|---|---|---|---|
| Tumor volume (ml) | 194 (±200) | 79 (±35) | 0.144 |
| Lung V5 (%) | 14 (±7) | 13 (±9) | 0.611 |
| Lung V10 (%) | 12 (±6) | 10 (±7) | 0.588 |
| Lung V20 (%) | 8 (±4) | 7 (±5) | 0.489 |
| Lung V30 (%) | 2 (±1) | 1 (±1) | 0.15 |
| Mean lung dose (cGy) | 334 (±150) | 290 (±164) | 0.512 |
| LDH (U/L) | 287 (±189) | 243 (±75) | 0.560 |
| CRP (mg/L) | 3.4 (±4.3) | 3.1 (±4.5) | 0.869 |
| * KL-6 (U/ml) | 388 (±246) | 659 (±590) | 0.095 |
lung V5: lung volume receiving >5 Gy; lung V10: lung volume receiving >10 Gy; lung V20: lung volume receiving >20 Gy; lung V30: lung volume receiving >30 Gy; LDH: lactate dehydrogenase; CRP: C-reactive protein; KL-6: Sialylated carbohydrate antigen KL-6.
* KL-6 was evaluated in 27 patients, including 20 who developed grade ≤ 1 pneumonitis and seven who developed grade ≥ 2 pneumonitis.